PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan

Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago "Finding a needle in a haystack - 4 molecules out of a million" NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the Alzheimer's Dr...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a drug development company focused on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a group of companies with a focus on the developme...

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

PALO ALTO, Calif., August 4, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This te...

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States

STAMFORD, Conn. and PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced entry into an exclusive license and collaboration agreement to commercialize Intermezzo ((R)) (z...

Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software

Terrosa Technologies, a provider of Cloud and SaaS migration services and SaaS based applications, announces it has exclusive world wide sales, marketing and distribution responsibilities with Integrated Clinical Solutions for its Inclinicalperform application. Inclinicalperform is software-as-a-...

Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets

PORTLAND, Ore., July 22 /PRNewswire/ -- Global One Principal Irl M. Davis today announced a relationship with Saigene Biotech, Inc. for the introduction and sale of a new class of harmful algae bloom detection technology in ASEAN nations, China, and Bangladesh. Global One, a consul...

Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens

Hygeia Therapeutics has added to its portfolio of topical hormonal modulators with the acquisition of a series of potent topical anti-androgens. The compounds are expected to be devoid of systemic activity and will be developed for skin and hair disorders associated with increased sensitivity to...

PDI and The Medical Affairs Company Enter Exclusive Strategic Alliance

SADDLE RIVER, N.J. and KENNESAW, Ga., June 3 /PRNewswire-FirstCall/ -- Two leaders in the pharmaceutical contract services industry, PDI, Inc. (Nasdaq: PDII ), a provider of sales and marketing support to U.S. pharmaceutical companies, and The Medical Affairs Company (TMAC(R)), the leading provi...

Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries

NEWTON, Mass., June 3 /PRNewswire-FirstCall/ -- Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTC Bulletin Board: MFLU), and POWREX Corporation have entered into an exclusive distributorship agreement whereby POWREX will market, sell and service Microfluidize...

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

Cytokinetics Receives Exercise Fee of $50 Million Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/ -- Cytokinetics Incorporated (Nasdaq: CYTK ) and Amgen Inc. (Nasdaq: AMGN ) ...

Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital

LA JOLLA, Calif., May 15 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights jointly owned by Children's Hospital Boston and Massachusetts General Hospital. This intellectual property covers compositions and methods for supportin...

NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases

License Strengthens NeoStem's Portfolio of Regenerative Treatments NEW YORK, May 11, /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it ha...

NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds

NEW YORK, May 4 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed an agreement to license the exclusive worldwide rights to an inno...

Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation

FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast cancer patients; Further strengthens Company's breast cancer menu ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Clarient, Inc. , (Nasdaq: CLRT ), a premier anatomic pathology and mol...

Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform

ST. LOUIS and MOUNTAIN VIEW, Calif., March 31 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL ) today announced an agreement to supply high quality services and oligonucleotides to Gene Oracle, an innovative gene synthesis company. Under the terms of the agreement, Sigma-Aldrich will be...

Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That 'Positive Cash Flow' Is Possible in '09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview

SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN), told the editors of The Wall Street Transcript, a New York City financial news weekly, that there is an excellent possibility that the company ...

Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*

ANTONY, France, March 24 /PRNewswire-FirstCall/ -- Stallergenes S.A. and Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary of Solvay Group) announce the signing of an exclusive partnership agreement for the promotion and distribution of Stallergenes diagnostic and treatment product...

Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor

Cancer Targeted Therapeutic for Samtheo's Personalized Medicine Portfolio NEW YORK, March 16 /PRNewswire/ -- Samtheo Biopharma LLC has entered into a license agreement, through its subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, gaining exclusive worldwide rights to a small mo...

Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market

TORONTO, March 9 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced that it has signed a license agreement with Toray Industries, Inc. of Japan granting Spectral the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic device for the t...

China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets

HARBIN, China, Feb. 24 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that its...

NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies

License enhances NeoStem's Presence in Anti-Aging Arena NEW YORK, Feb. 23 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Alternext US: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has sign...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced...

S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317

SINGAPORE and SAN DIEGO, Jan. 21 /PRNewswire/ -- S*BIO Pte Ltd and Tragara Pharmaceuticals Inc. today announced that S*BIO has granted a worldwide exclusive license to Tragara to develop and commercialize its novel multi-kinase inhibitor SB1317. Under the terms of the agreement S*BIO is elig...

Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry

NEW YORK, Jan. 14 /PRNewswire/ -- With all the woes of the U.S. economy, many people and businesses are looking to China for better opportunities. After all, China is expected to become the fifth-largest pharmaceutical market in the world by 2010. As the world watches, China is becoming a drivin...

Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.

REHOVOT, Israel and JERSEY CITY, New Jersey, January 8 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today it has signed an exclusive distribution agreement with Teva Pharmaceutical Industries Ltd. Under...

Nikon Instruments Introduces Exclusive VAAS Detector Imaging Method for Confocal Microscopy

Unique Technology Greatly Improves Signal to Noise MELVILLE, N.Y., Dec. 15 /PRNewswire/ -- Nikon Instruments, Inc. ( www.nikoninstruments.com ) today launched VAAS Detection, a new, exclusive confocal imaging method for post acquisition recovery of data normally lost during the course of...

Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts

HAMBURG, Germany, December 11 /PRNewswire/ -- Olympus has further cemented its position as a leader in the field of minimally invasive surgery by signing an exclusive and immediate deal to distribute the products of Irish company Advanced Surgical Concepts worldwide. ASC is the sole global provide...

FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract

ALEXANDRIA, Va., Dec. 9 /PRNewswire-USNewswire/ -- First Coast Service Options (FCSO) has selected Burgess, recognized as an industry leader in Medicare reimbursement solutions, to support a new Medicare contract awarded recently by the Centers for Medicare & Medicaid Services (CMS). ...

Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics

OMAHA, Neb. and HOUSTON, Dec. 2 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced that Transgenomic has signed a letter of intent to acquire exclusive rights for Power3 Medical's Neurodegenerative Bi...

VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research

International Agreement Licenses Seno's Opto-Acoustic Imaging Technology To VisualSonics to Enable Molecular Imaging at the Cellular Level and Aid in the Pursuit of Neurology, Regenerative Medicine, Inflammation, and Cancer Applications TORONTO and SAN ANTONIO, TX, Nov. ...

GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines

VIENNA, Austria, October 23 /PRNewswire/ -- GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced today the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS's Alzheimer's disease vaccine programmes, aimed at treating Alzheimer's by targeting beta-amyl...

Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xi'an Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinba's Total Profit

XI'AN, China, Oct. 7 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB; the "Company"), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production in Xi'a...

The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System

The HeartAssist 5™ Pediatric VAD will be introduced for the first time in the U.S. at the 16th annual meeting of the International Society for Rotary Blood Pumps (ISRBP) in Houston on Oct. 2-4. HOUSTON (Business Wire EON) September 30, 2008 -- The Modern DeBakey...

Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds

ST. LOUIS, Sept. 11 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into an exclusive agreement with IsoSciences, LLC, to distribute isotopically labeled bioactive compounds and their metabolites ( http://www.sigma-aldrich.com/isotope ) through its Al...

CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine

VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global pharmaceutical company, under which CEL-SCI has granted Teva an exclusive...

ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells

ATHENS, Georgia, Aug. 19 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has entered into an exclusive worldwide technology licensing agreement with the University of Georgia Research Foundation that will enable the compan...

PolyOne Corporation Announces an Exclusive License Agreement with Battelle for Bio-Plasticizer Technology

AVON LAKE, Ohio, Aug. 5 /PRNewswire-FirstCall/ -- PolyOne Corporation (NYSE: POL ), a premier provider of specialized polymer materials, services and solutions, announced today that it has entered into an exclusive license arrangement for a series of bio-based plasticizer technology patents o...

[video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.net's 3-Minute Press Show

WATERLOO, Ontario, July 31 /PRNewswire-FirstCall/ -- TurboSonic Technologies, Inc. (OTC Bulletin Board: TSTA), a global leader in the design and supply of industrial air pollution control technologies, today announced that the company's CEO, Edward Spink is featured in an exclusive interview o...

Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets

AMSTERDAM, The Netherlands and BARCELONA, Spain, July 15 /PRNewswire-FirstCall/ -- Agendia BV and Ferrer inCode today announced an agreement that will give Ferrer exclusive rights to sell two of Agendia's signature cancer diagnostic services -- MammaPrint(R), a prognostic test that uses a 70-g...

AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy

AMSTERDAM, The Netherlands, July 15 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the start of a collaboration with St. Jude Children's Research Hospital in Memphis, Tennessee, USA, on the development of...